SRR934728
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 45.137976346911955
- age_years
- 37
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.512
- TGF_BETA_SIGNALING+0.398
- MYC_TARGETS_V1+0.308
- MITOTIC_SPINDLE+0.293
- PROTEIN_SECRETION+0.233
- DNA_REPAIR+0.230
- G2M_CHECKPOINT+0.218
- WNT_BETA_CATENIN_SIGNALING+0.218
- MYC_TARGETS_V2+0.202
- UV_RESPONSE_DN+0.180
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.354
- INFLAMMATORY_RESPONSE-0.338
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.307
- COMPLEMENT-0.279
- TNFA_SIGNALING_VIA_NFKB-0.266
- OXIDATIVE_PHOSPHORYLATION-0.259
- IL6_JAK_STAT3_SIGNALING-0.257
- MYOGENESIS-0.247
- ESTROGEN_RESPONSE_LATE-0.239
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.232
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934847 | — | — | 0.884 |
| 2 | 7C225672-8372-4202-A749-3D8E9A0747CC | — | — | 0.883 |
| 3 | 589A94F8-2432-4D6D-94EB-B327ECA291AF | — | — | 0.883 |
| 4 | E6090BC6-D29D-4401-990A-251930CC6853 | — | — | 0.872 |
| 5 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.865 |
| 6 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.863 |
| 7 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.859 |
| 8 | A130FABA-F55F-412D-940E-7305057B4D1A | — | — | 0.856 |
| 9 | SRR934951 | — | — | 0.849 |
| 10 | SRR934805 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.512 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.398 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.308 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.293 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.233 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.218 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.218 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.202 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.176 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.176 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.055 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.054 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.042 | Inavolisib | — uncovered |
| PEROXISOME | 0.028 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.002 | Inavolisib | — uncovered |